Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Jan 17, 2025

Dividend Increases/Decreases for the Week of January 17
Let's take a look at firms raising/lowering their dividends this week.

Nov 1, 2024

Dividend Increases/Decreases for the Week of November 1
Let's take a look at firms raising/lowering their dividends this week.

Feb 2, 2024

Earnings Roundup: ABBV, CVX, NYCB, XOM
Image: Unrealized losses continue to mount for banking entities due to the Fed's rate-hiking cycle. "Unrealized losses on securities totaled $683.9 billion in third quarter, up $125.5 billion (22.5 percent) from the prior quarter, primarily due to an increase in mortgage rates that reduced the value of mortgagebacked securities. Unrealized losses on held-to-maturity securities totaled $390.5 billion in the third quarter, while unrealized losses on available-for-sale securities totaled $293.5 billion." -- Image Source: FDIC Quarterly.AbbVie is facing pressure from declining sales of Humira, but the company's long-term outlook looks fine to us bolstered by promising growth of Skyrizi and Rinvoq. Chevron put up mixed fourth-quarter 2023 results, but its free cash flow easily covers its dividend payout. We've grown cautious on Chevron due to its deal making, however. New York Community Bancorp is provisioning for greater credit losses, while its net interest margin is under pressure. The bank recently slashed its payout, and we continue to reiterate why we don't like the dividends of banking firms. Exxon Mobil put up an excellent 2023, and while the firm's dividend is in great shape, we no longer are pursuing new energy-related ideas in the newsletter portfolios at this time.

Jan 19, 2024

Stock Reports on 25 Dividend Kings to Pad Your Dividend Growth Portfolio
Image Source: Jason Train. Investors love dividends! After all, research has shown that companies that have paid an ever-increasing dividend for a long time do quite well in the stock market. In this note, you can download the stock reports of 25 Dividend Kings, or stocks that have raised their dividends in each of the past 50 years!

Jan 12, 2024

Dividend Increases/Decreases for the Week of January 12
Let's take a look at firms raising/lowering their dividends this week.

Oct 27, 2023

Dividend Increases/Decreases for the Week of October 27
Let's take a look at firms raising/lowering their dividends this week.

Sep 24, 2023

Report Updates: Amazon Registers the Lowest Rating on Our Scale
Check out the latest report updates on the website. The biggest takeaway of this refresh is that Amazon is poised to generate significantly negative free cash flow in 2023, and while we think the firm will turn this measure around materially in the long haul, shares are coming out as overvalued on our discounted cash-flow process, while technically its stock price is breaking down. An overvalued stock on both an absolute and relative value basis with negative technical/momentum indicators registers the worst rating on our methodology, the Valuentum Buying Index (1=worst, 10-best).

Jun 12, 2023

FDA Accepts License Application for Vertex Pharma’s and CRISPR Therapeutics’ Key Investigational Treatment
Image: Vertex's pipeline is impressive. We like its areas of focus and the progress it continues to make with key therapies in CRISPR and pain management. The combination of robust financials and a tremendous pipeline of game-changing therapeutics from exa-cel to VX-548 makes Vertex Pharma a no-brainer idea for the Best Ideas Newsletter portfolio, in our view. Vertex Pharma's shares are up nearly 18% so far in 2023, and we think its long term remains very bright. The company's dominance in CF gives it moaty economic characteristics, while the possible launch of as many as five new products in the next five years offers tremendous promise. Vertex Pharma's risk-reward situation continues to be skewed positively in investors' favor.

May 17, 2023

Our Reports on the Health Care Bellwethers Industry
Our reports on the Health Care Bellwethers industry can be found in this article. Reports include JNJ, CVS, ABT, ABBV, LLY, AMGN, MRK, PFE, VRTX, UNH, BMY, GILD, ISRG, MDT, WBA, ZTS.

Apr 14, 2023

UnitedHealth Group Raises Guidance for 2023
Image: We view valuation as a range of probable fair value outcomes. The high end of the fair value estimate range for UnitedHealth Group stands north of $600. Shares are currently trading at ~$520 each at the time of this writing. We’re huge fans of entities that generate strong free cash flow and boast a healthy net cash position on the books, and that includes UnitedHealth Group. During the first quarter of 2023, the company returned $3.5 billion to shareholders via dividends and buybacks. UnitedHealth remains one of our top dividend growth ideas, and while the company yields just ~1.3% at this time, we expect its future pace of dividend growth to be robust, especially in light of its strong potential earnings expansion that is backed by robust free cash flow generation and a net-cash-rich balance sheet. It’s simply hard not to like UnitedHealth Group.